Latest News
- September 20, 2013
- Approval received for Flutiform, a combination drug for asthma treatment
- July 30, 2013
- Consolidated Financial Results (For the First Quarter Ended June 30,2013)- Supplementary Information
- July 30, 2013
- Summary of Consolidated Financial Results (For the First Quarter Ended June 30,2013)[Japanese Standard]
- May 9, 2013
- Financial Results for the Fiscal 2012, the Year Ended March 31, 2013- Supplementary Information
- February 4, 2013
- Consolidated Financial Results (For the Third Quarter Ended December 31,2012)- Supplementary Information
- February 4, 2013
- Summary of Consolidated Financial Results (For the Third Quarter Ended December 31,2012)[Japanese Standard]
- November 7, 2012
- Consolidated Financial Results (For the Second Quarter Ended september 30,2012)- Supplementary Information
- November 7, 2012
- Summary of Consolidated Financial Results (For the Second Quarter Ended september 30,2012)[Japanese Standard]
- October 9, 2012
- Announcement regarding transfer of "Pekiron Cream 0.5%" topical antifungal medication business.
- September 25, 2012
- Application filed for KRP-108, an Anti-asthmatic Treatment, in Japan
- July 31, 2012
- First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2013
- May 28, 2012
- Establishment of a Subsidiary
- May 9, 2012
- Financial Results for the Fiscal 2011, the Year Ended March 31, 2012- Supplementary Information
- April 20, 2012
- Launch of "AIPHAGANR Ophthalmic Solution 0.1%" for the treatment of Glaucoma / Ocular Hypertension, in Japan
- February 3, 2012
- Third Quarter Consolidated Financial Results for the Ending Fiscal Year March 31, 2012
- February 3, 2012
- Summary of Consolidated Financial Results(For the Third Quarter Ended December 31, 2011) [Japanese Standard]
- November 8, 2011
- Kyorin Pharmaceutical and Daiichi Sankyo Brasil Reach Agreement in Brazil for Activities Related to the Development and Marketing of Imidafenacin
- November 8, 2011
- Summary of Consolidated Financial Results (For the Second Quarter Ended september 30,2011)[Japanese Standard]
- November 8, 2011
- Consolidated Financial Results (For the Second Quarter Ended september 30,2011)- Supplementary Information
- August 22, 2011
- First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2012
- August 11, 2011
- Summary of Consolidated Financial Results(For the First Quarter Ended June 30, 2011)
- May 11, 2011
- Financial Results for the Fiscal 2010, the Year Ended March 31, 2011- Supplementary Information
- February 24, 2011
- Kyorin signed a License Agreement with Almirall on COPD Therapeutic Agent "Aclidinium Bromide" for Japan Territory
- February 21, 2011
- KYORIN Group's Participation in Environmental Hygiene
- February 15, 2011
- Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2011
- February 8, 2011
- Summary of Consolidated Financial Results (For the Third Quarter Ended December 31, 2010) [Japanese Standard]
- November 17, 2010
- Summary of Consolidated Financial Results (For the Second Quarter Ended September 30,2010)[Japanese Standard]
- November 12, 2010
- Approval Received for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder
- November 8, 2010
- Extension of License Rights Regarding KRP-203
- September 21, 2010
- Regarding Today's Media Report
- July 30, 2010
- First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2011
- June 8, 2010
- RELEASE OF "MUCODYNE® DS50%"
- May 26, 2010
- Change of Business Name
- February 3, 2010
- Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2010
- January 18, 2010
- MARKETING APPROVAL FOR "MUCODYNE® DS50%"
- January 7, 2010
- Application filed for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder
- November 5, 2009
- Execution of License Agreement on Neramexane for Tinnitus with Merz Pharmaceuticals for Japan Territory
- September 29, 2009
- KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries
- August 5, 2009
- First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2010